Across TCGA pan-cancer cohorts, RN7SL565P RNA is linked to patient survival in 2 of 34 cancer types, making it the most broadly survival-associated RN7SL565P data layer.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RN7SL565P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RN7SL565P expression acts as an unfavorable survival marker.
BLCA and PAAD are the cancer types where RN7SL565P RNA most reproducibly stratifies survival.